Wilkins Investment Counsel Inc. Acquires 240 Shares of Eli Lilly and Company (NYSE:LLY)

Wilkins Investment Counsel Inc. increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 8.4% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,104 shares of the company’s stock after purchasing an additional 240 shares during the quarter. Wilkins Investment Counsel Inc.’s holdings in Eli Lilly and Company were worth $2,810,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. AMJ Financial Wealth Management acquired a new position in Eli Lilly and Company in the 4th quarter worth $201,000. Aveo Capital Partners LLC lifted its holdings in shares of Eli Lilly and Company by 8.2% in the fourth quarter. Aveo Capital Partners LLC now owns 2,020 shares of the company’s stock valued at $1,178,000 after purchasing an additional 153 shares in the last quarter. Gryphon Financial Partners LLC boosted its position in shares of Eli Lilly and Company by 19.4% during the fourth quarter. Gryphon Financial Partners LLC now owns 2,324 shares of the company’s stock worth $1,355,000 after buying an additional 377 shares during the period. Main Street Financial Solutions LLC boosted its position in shares of Eli Lilly and Company by 2.5% during the fourth quarter. Main Street Financial Solutions LLC now owns 876 shares of the company’s stock worth $511,000 after buying an additional 21 shares during the period. Finally, FUKOKU MUTUAL LIFE INSURANCE Co grew its holdings in shares of Eli Lilly and Company by 22.0% during the fourth quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 5,914 shares of the company’s stock worth $3,447,000 after buying an additional 1,068 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 1,441 shares of the business’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $915.02, for a total transaction of $1,318,543.82. Following the completion of the sale, the insider now owns 97,367,369 shares in the company, valued at $89,093,089,982.38. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders sold 646,878 shares of company stock worth $591,465,138 over the last three months. Insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on LLY. Morgan Stanley restated an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Wells Fargo & Company increased their target price on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. JPMorgan Chase & Co. boosted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Truist Financial restated a “buy” rating and set a $1,000.00 price objective (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $977.35.

Eli Lilly and Company Stock Down 1.2 %

LLY stock opened at $923.71 on Friday. Eli Lilly and Company has a 1-year low of $516.57 and a 1-year high of $972.53. The business’s 50 day simple moving average is $897.12 and its 200 day simple moving average is $833.36. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The firm has a market capitalization of $877.92 billion, a PE ratio of 136.04, a PEG ratio of 2.79 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, research analysts anticipate that Eli Lilly and Company will post 16.49 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th were issued a $1.30 dividend. The ex-dividend date was Thursday, August 15th. This represents a $5.20 annualized dividend and a yield of 0.56%. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.